L-FABP as a Potential Biomolecular Marker of Liver Graft Injury
Journal of Clinical Medicine · 20.10.2025 · 14 (20) · 7404
DOI: 10.3390/jcm14207404 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 20.10.2025. Verfasst von Ana Kalamutova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Abdominal Surgery, University Medical Centre Ljubljana, Zaloska 7, 1000 Ljubljana, Slovenia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UMC Ljubljana.
Abstract (Originalsprache)
Background
In recent years, indications for liver transplantation have expanded, while the age of transplant recipients has significantly increased due to improvements in perioperative management. As clinical manifestations of posttransplant complications vary and are often nonspecific, the identification of appropriate biomarkers is important for the assessment of graft quality and early recognition of potential complications following liver transplantation. Liver-type FABP (L-FABP) is a small cytoplasmic protein found abundantly in hepatocytes and is involved in the intracellular transport of long-chain fatty acids. Elevated serum levels have been detected in acute and chronic liver failure, kidney failure, and some malignancies. Materials and Methods: We conducted a prospective, single-center study from July 2023 to January 2025, including 29 adult patients who underwent deceased-donor transplantation. Three patients were excluded due to inadequate sample withdrawals. Serum L-FABP was measured preoperatively and on postoperative days 1, 3, 5, 7, and 14. Clinical, surgical, and biochemical data were collected and analyzed using non-parametric statistical tests.
Results
L-FABP levels were significantly higher on POD 7 in recipients of grafts from donors ≥ 65 years (p = 0.035), with no corresponding changes in standard liver function markers. While no significant differences in L-FABP levels were found between patients with and without infectious biliary or vascular complications (all p > 0.05), we proved a strong negative correlation between intraoperative blood transfusion volume and L-FABP levels on POD 5 (ρ = −0.677, p < 0.001) and POD 7 (ρ = −0.455, p = 0.025).
Conclusions
Our findings suggest that L-FABP holds promise as a biomarker for the early detection of subclinical hepatic graft cellular injury, which is not detected by means of conventional biomarkers for liver function.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Abdominal Surgery, University Medical Centre Ljubljana, Zaloska 7, 1000 Ljubljana, Slovenia.
- Faculty of Medicine, University of Ljubljana, Vrazov Trg 2, 1000 Ljubljana, Slovenia.
- Institute of Clinical Chemistry and Biochemistry, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.
- Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia.
ORCID-Profile: Ana Kalamutova, Ales Jerin, Miha Petric
Förderung
- UMC Ljubljana
Zitieren
APA
Kalamutova, A., Plevel, D., Djokic, M., Jerin, A., Trotovšek, B., & Petric, M. (2025). L-FABP as a Potential Biomolecular Marker of Liver Graft Injury. Journal of Clinical Medicine, 14(20), 7404. https://doi.org/10.3390/jcm14207404
Vancouver
Kalamutova A, Plevel D, Djokic M, Jerin A, Trotovšek B, Petric M. L-FABP as a Potential Biomolecular Marker of Liver Graft Injury. Journal of Clinical Medicine. 2025;14(20):7404. doi:10.3390/jcm14207404
BibTeX
@article{Kalamutova2025,
author = {Kalamutova, Ana and Plevel, Danaja and Djokic, Mihajlo and Jerin, Ales and Trotovšek, Blaž and Petric, Miha},
title = {L-FABP as a Potential Biomolecular Marker of Liver Graft Injury},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {20},
pages = {7404},
doi = {10.3390/jcm14207404}
}
EUVIMED